International Business News - SPPI http://www.ibtimes.com All articles are copyrighted by IBTimes.com 400 100 http://www.ibtimes.com/ http://www.ibtimes.com/images/top_logo_ibt2_3.gif Cell Therapeutics Inc. said Monday the Food and Drug Administration granted priority review for an application seeking expanded use of the biotechnology company's cancer drug Zevalin. http://www.ibtimes.com/articles/20081201/cell-therapeutics-gets-fda-priority-review-on-drug.htm Mon, 01 Dec 2008 07:32:38 EST Spectrum Pharmaceuticals Inc. and Cell Therapeutics Inc. said Wednesday they are starting a joint venture to ramp up U.S. sales of the cancer drug Zevalin. http://www.ibtimes.com/articles/20081126/spectrum-and-cell-therapeutics-to-market-zevalin.htm Wed, 26 Nov 2008 14:52:35 EST Spectrum Pharmaceuticals Inc. said Friday it has asked the Food and Drug Administration to approve its Fusilev for patients who suffer from vitamin deficiency after getting chemotherapy for colorectal cancer. http://www.ibtimes.com/articles/20081031/spectrum-asks-fda-for-expanded-fusilev-approval.htm Fri, 31 Oct 2008 15:31:26 EDT Spectrum Pharmaceuticals Inc. said Wednesday it stands to receive up to $345.5 million plus potenial royalty payments under a development and marketing deal for a bladder cancer drug with Botox maker Allergan Inc. http://www.ibtimes.com/articles/20081029/allergan-and-spectrum-in-bladder-cancer-drug-pact.htm Wed, 29 Oct 2008 14:04:40 EDT German biotechnology company GPC Biotech AG said Friday its European partner withdrew an application for the troubled cancer drug candidate satraplatin, a move made by GPC in the U.S. last year. http://www.ibtimes.com/articles/20080725/gpc-partners-pull-cancer-drug-application.htm Fri, 25 Jul 2008 18:19:20 EDT Cancer drugs developer Spectrum Pharmaceuticals Inc. said Tuesday its first-quarter net loss widened as a result of increased research and development expenses. http://www.ibtimes.com/articles/20080513/spectrum-pharmaceuticals-1q-loss-grows-on-expenses.htm Tue, 13 May 2008 09:40:58 EDT Par Pharmaceutical Cos. said Wednesday it will pay Spectrum Pharmaceuticals Inc. $20 million in cash for its stake in a generic migraine injection. The payment will give Par 95 percent of the profits from the generic version of GlaxoSmithKline's Imitrex injection, up from its prior 38 percent stake. http://www.ibtimes.com/articles/20080507/par-to-pay-spectrum-20m-for-its-stake-in-generic-injection.htm Wed, 07 May 2008 09:56:17 EDT